Exchange: NASDAQ·Updated 07:30 PM EDT

MSLE Satellos Bioscience Inc

$7.49
$0.145
(1.97%)
Today
Closed $7.49
$0.00
(0.00%)
After Hours
Mkt Cap$158.91M
Vol59,901.00

About MSLE

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.
52

Neutral Sentiment

How do you feel about MSLE?

Florestan
$MSLE the primary endpoint is safety. I guess you want them to push out a PR claiming it is safe? Very useful. Just sit back and wait for the full dataset like the rest of us.
5
focafoca99
$MSLE obtained FDA IND clearance for forazapadin in FSHD and a $5M partnership with the FSHD Canada Foundation.
5
obryanjfg
$MSLE Here is the phase 2 primaries. This is the study they moved from Q4 to Q1. They announced full enrollment on 9/30 so they physically will not have data by the EOY. 1 month for test and 3 months for dosing to the 1st readout. No conspiracy, just schedule slipped on recruitment. Safety yes, but also arm strength. For such a short duration, PBO will look steady (maybe up slightly due to PBU effect) and drug arm, if like the other previous small studioes, could have a solid jump. This would set them up well for a successful sttudy and a AA NDA.
4
obryanjfg
$MSLE Ham, they announced on 9/30, that they completed enrollemnt, Was N=51 but they over recruited so now its 51+ but we don't know the exact number. The trial is 1M predose for test and dose at T+1M and at T+4M top line results. So that puts it earliest 1/31 +/- 1 or 2D. Prevously they said top line in Q4. It could only have been late Q4 bcs they've said recruitiment would be done iin Q4. So they slipped a coupel weeks for lord know what reason. I suppose they could have dosed all by 9/30 which put Top line at 12/31 (New years Eve) if they spend 0 hours accumulating the data. Relax its Jan most likely for a fullset of data.
4
HamBoneXoXo
$MSLE Pushed data back by a quarter claiming they want to do thorough analysis of the data. My reply is thorough analysis my ass. The top line data can be extracted out of the database in no time and doesn’t need a quarter. Release top line and then study the data for yrs if you wish. The trial had a primary and secondary end point. All one needs to know is did you meet those endpoints. There behavior suggests they really don’t have a clear feel for the drug.
1
1
focafoca99
$MSLE stated enrollment is complete for its BASECAMP Phase 2 DMD trial, targeting data readout in Q1 2027.
4
obryanjfg
$MSLE I will say this. In my many years of losing $ left and right; NOW is the time fear is spread, to drive the price down before a major data release, ESP for a TAM as large as this one. I expect its even gonna get worse; the HF will not let this slide w/o some pain to go around before the phase 2 data release.
3
PennyScam
$MSLE Good for that guy. If he was wise, I suggest Big E should be interested in what some other dumb folk like me are thinking about. I’ve noticed Satellos on the circuit looking for money. I see Andrew Rae on the circuit purely acting as a poster boy, rubbing shit in, but also maybe acting as a bridge between a couple of parties. Who knows right. Not me. So many friendly faces floating around. Lots of folk on the circuit. I’m a Bertilumumab guy. I like ICO. That other drug stuff is showing potential but not my bag. Bloom is here for what I’m waiting here for. He better be with that much cheddar in the game. I’m still working on this one deal that could possibly give me direct ownership without lifting a finger. I just had to do one thing people. Just one simple thing. It’s super incredible people. Wait for it………. it’s big………………..keep waiting………………it’s right around the corner. Ok. Here it is……BUY and HOLD and DON’T SELL one share for 12 years. Simple. Ck
1
PennyScam
$MSLE Hey. 👋. You guys are so focused on studies. How’s the ICO stuff coming along. How’s the monetizing of Bert. That’s where you will make your money. Just my opinion. But you guys keep talking about your studies. I for one couldn’t give a flying fuuuuuck about this company. I care only about the black box called Bertiliumumab and its ophthalmology indication. Do not think for one second Brian invested in this heel for shits and giggles based of some unproven shit. Not in these special times. Dry powder is hard to come by. That’s a move with intention and purpose. So either Brian is as dumb as they come for investment bankers, plenty of dumb ones out there. Anyone can have money and allocate it. It’s purposeful delicate moves that generate wealth. You guys know this shit. Best to you geniuses. Keep updating us. This is a nice Long hold pending on how certain invidividuals want to move. Fun times people. Ck

Advertisement|Remove ads.